Nexus Surgical Q1 FY27: Income up 49%, PAT 34%

What the board approved on 13 August 2026

Nexus Surgical And Medicare Ltd (BSE: 538874) informed exchanges that its Board of Directors approved the unaudited standalone financial results for the quarter ended 30 June 2026. The board meeting was held on Thursday, 13 August 2026. The company also indicated that the results were reviewed by the auditors, alongside a limited review report.

The announcement matters for investors tracking quarterly momentum in small-cap healthcare and medical supplies names, where earnings visibility is often limited and corporate disclosures are a key input. The company’s update also followed earlier communication that the board would meet on 13 August 2026 at 4:00 pm to consider and approve the same set of unaudited quarterly numbers.

Q1 FY27 headline numbers: income, profit, and EPS

For Q1 FY27 (quarter ended 30 June 2026), Nexus Surgical & Medicare reported total income of ₹2.58 crore. In the same disclosure set, total income was also stated as ₹257.59 lakh, which equals ₹2.58 crore when converted to a single base unit.

Net profit for the quarter was reported at ₹20.42 lakh, equivalent to ₹0.20 crore. Earnings per share (EPS) for the quarter was stated as ₹0.37.

The company also provided year-on-year (YoY) growth rates for the quarter. It said total income increased 49.31% YoY, while net profit rose 33.90% YoY.

The meeting schedule and trading window closure

Before the outcome was filed, Nexus Surgical and Medicare Ltd had notified that its board meeting was scheduled on 13 August 2026 at 16:00. The stated purpose was to consider and approve unaudited quarterly financial results for the quarter ended 30 June 2026.

The company also disclosed a trading window closure till 15 August 2026. This is typically communicated around results periods as part of compliance practices for insider trading regulations and internal codes of conduct.

Stock price references in the disclosure stream

In the data shared alongside the corporate actions and outcome references, the stock was shown trading at ₹19.82 per share for Nexus Surgical and Medicare Ltd (NEXUSSURGL). Separately, the stream also included price points and a one-day move: the share price was noted as down by 2.64% from a previous close of ₹18.50, with the last traded price shown as ₹18.01.

Another market snapshot at the top of the text showed “19.49” and “1.30 (7.15%)”. The disclosure extract does not specify the timestamp for this specific line, but it indicates a price level and percentage change as captured in the feed.

Key financials table (all amounts in ₹ crore)

How this compares with earlier disclosed results (FY26 and FY25 references)

The provided text also points to earlier board-meeting outcomes and reporting cadence. A table of meeting history included entries such as 28 May 2026 (audited results), 14 February 2026 (quarterly results), and 14 November 2025 (quarterly results), among other dates.

For 14 November 2025, the disclosure stream included specific numbers for Q2 and H1 FY2025 (quarter and half year ended 30 September 2025). It stated Q2 sales of ₹1.17 crore (₹116.58 lakh), H1 sales of ₹2.89 crore (₹289.11 lakh), and H1 profit after tax (PAT) of ₹0.33 crore (₹32.61 lakh). These historical figures provide a reference point for how the company has been reporting performance across periods, based on the text available.

Corporate governance context: AGM and board processes

Beyond quarterly results, the text mentions that Nexus Surgical and Medicare Limited’s 34th AGM passed resolutions related to financial statements, director appointment, and secretarial auditors. It also states that all three ordinary resolutions were passed with a substantial majority. Separately, it references that the board approved the Directors’ Report and fixed the AGM date.

These items add context on the company’s routine governance milestones, which often sit alongside earnings updates in the corporate announcement trail.

Market impact: what investors can take from the numbers

From the disclosed Q1 FY27 figures, the key takeaway is that the company reported YoY growth in both total income and net profit, with income growth higher than profit growth for the quarter. With EPS reported at ₹0.37, investors have an additional per-share metric to map against price snapshots shown in the same information stream.

On the compliance side, the clearly stated meeting time, agenda, and trading window closure dates indicate a structured reporting process around quarterly results. The presence of an auditor review note is also part of the standard result-filing package highlighted in the text.

Analysis: why the Q1 filing matters for tracking momentum

For smaller listed companies, quarter-ended disclosures often serve as the primary public window into operating trends. In this case, the company’s filing provides three core data points for Q1 FY27: total income, net profit, and EPS, along with YoY growth rates for income and profit.

The same disclosure stream also shows how the company has maintained a sequence of board meetings for audited and quarterly results across FY25 and FY26. While the text does not provide a full multi-quarter breakdown for FY27, it gives enough information for readers to anchor Q1 FY27 performance against the company’s earlier reported Q2 and H1 FY2025 sales and PAT figures.

Conclusion

Nexus Surgical & Medicare said its board approved unaudited standalone results for Q1 FY27 at the 13 August 2026 meeting, reporting total income of ₹2.58 crore and net profit of ₹0.20 crore with EPS of ₹0.37. The company had earlier scheduled the meeting for 4:00 pm on the same date and disclosed a trading window closure till 15 August 2026. Any further detail beyond the headline figures would depend on additional filings and attachments released with the quarterly results package.